{"title": "Ayurveda medicine for the treatment of Parkinson's disease", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2023-09-20", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Ayurveda medicine for the treatment of Parkinson's disease\n- Autores\n-\n[P\u00e9rez Lloret, Santiago](/vufind/Author/Home?author=P%C3%A9rez+Lloret%2C+Santiago); [Rey, Ver\u00f3nica](/vufind/Author/Home?author=Rey%2C+Ver%C3%B3nica); [Rascol, Olivier](/vufind/Author/Home?author=Rascol%2C+Olivier)\n- A\u00f1o de publicaci\u00f3n\n- 2013\n- Idioma\n- ingl\u00e9s\n- Tipo de recurso\n- art\u00edculo\n- Estado\n- versi\u00f3n publicada\n- Descripci\u00f3n\n- Fil: P\u00e9rez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacolog\u00eda Cl\u00ednica y Neurociencias; Francia\nFil: P\u00e9rez Lloret, Santiago. Pontificia Universidad Cat\u00f3lica Argentina. Facultad de Medicina. Laboratorio de Cl\u00ednica Farmacol\u00f3gica y Epidemiolog\u00eda; Argentina\nFil: Rey, Ver\u00f3nica. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacolog\u00eda Cl\u00ednica y Neurociencias; Francia\nFil: Rey, Ver\u00f3nica. Pontificia Universidad Cat\u00f3lica Argentina. Facultad de Medicina. Laboratorio de Cl\u00ednica Farmacol\u00f3gica y Epidemiolog\u00eda; Argentina\nFil: Rascol, Olivier. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacolog\u00eda Cl\u00ednica y Neurociencias; Francia\nAbstract: Abstract In most western countries, the symptomatic management of Parkinson\u2019s Disease (PD) is usually achieved with medicinal products including levodopa (LD), dopamine agonists, MAO\u2010B inhibitors, COMT inhibitors, antimuscarinics and amantadine. The control of the quality of the production of such medications is strict and the assessment of the benefit\u2010risk ratio of these interventions is regulated by official recommendations which follow an evidence\u2010based approach. Ayurveda Indian medicine has used Mucuna Pruriens (MP) for the treatment of PD since ancient times. MP includes LD as an active moiety, among many others. A literature search was conducted between 1978\u20102012 with the keywords Parkinson\u2019s disease, ayurveda or mucuna pruriens. MP antagonized the effects of 6OHDA lesions in rats and when administered chronically it showed lower dyskinetic potential compared to L\u2010DOPA. MP also reduced Parkinsonian symptoms in an MPTP treated monkey with less dyskinesias compared to L\u2010DOPA. Four clinical trials of MP for PD treatment were found. Initially they were open\u2010label, uncontrolled studies, suggesting that MP might reduce parkinsonism severity. One double\u2010blind randomized crossover study was conducted in 8 PD patients, employing acute challenges of levodopa or MP. It showed that the effect of MP had a faster onset than LD, with shorter latencies to peak and increased on\u2010time. No other medium\u2010term (i.e., 6 months) randomized\u2010controlled trials (RCT) are available. According to the MDS EBM taskforce working procedures, an intervention is considered as \u201cefficacious\u201d when there is at least one high quality randomized controlled trial (RCT) showing a positive effect on studied outcomes with no conflicting data from other RCTs. Based on these premises, there is insufficient evidence to conclude the efficacy of MP in the treatment of PD. Thus its use in clinical practice remains open to investigation. It must also be emphasized that various MP formulations can be used, raising concerns about their quality, which is difficult to control, as regulation is limited. Impurities or variations in active moieties, can lead to unexpected adverse drug reactions. In conclusion, the use of MP in PD treatment remains open to investigation and thus cannot be recommended for clinical use\n- Fuente\n- International Journal of Integrative Medicine 2013, 1 (6)\n- Materia\n-\nMEDICINA AYURVEDA\nENFERMEDAD DE PARKINSON\nTRATAMIENTO\nENFERMEDADES NEUROGENERATIVAS\n- Nivel de accesibilidad\n- acceso abierto\n- Condiciones de uso\n- https://creativecommons.org/licenses/by-nc-sa/4.0/\n- Repositorio\n- Instituci\u00f3n\n- Pontificia Universidad Cat\u00f3lica Argentina\n- OAI Identificador\n- oai:ucacris:123456789/1622\n[Ver los metadatos del registro completo](#collapseDetail)\n|id||\nRIUCA_b5c33442405717d8e78d138e09bd5997\n|\n|oai_identifier_str||\noai:ucacris:123456789/1622\n|\n|network_acronym_str||\nRIUCA\n|\n|repository_id_str||\n2585\n|\n|network_name_str||\nRepositorio Institucional (UCA)\n|\n|spelling||\nAyurveda medicine for the treatment of Parkinson's diseaseP\u00e9rez Lloret, SantiagoRey, Ver\u00f3nicaRascol, OlivierMEDICINA AYURVEDAENFERMEDAD DE PARKINSONTRATAMIENTOENFERMEDADES NEUROGENERATIVASFil: P\u00e9rez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacolog\u00eda Cl\u00ednica y Neurociencias; FranciaFil: P\u00e9rez Lloret, Santiago. Pontificia Universidad Cat\u00f3lica Argentina. Facultad de Medicina. Laboratorio de Cl\u00ednica Farmacol\u00f3gica y Epidemiolog\u00eda; ArgentinaFil: Rey, Ver\u00f3nica. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacolog\u00eda Cl\u00ednica y Neurociencias; FranciaFil: Rey, Ver\u00f3nica. Pontificia Universidad Cat\u00f3lica Argentina. Facultad de Medicina. Laboratorio de Cl\u00ednica Farmacol\u00f3gica y Epidemiolog\u00eda; ArgentinaFil: Rascol, Olivier. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacolog\u00eda Cl\u00ednica y Neurociencias; FranciaAbstract: Abstract In most western countries, the symptomatic management of Parkinson\u2019s Disease (PD) is usually achieved with medicinal products including levodopa (LD), dopamine agonists, MAO\u2010B inhibitors, COMT inhibitors, antimuscarinics and amantadine. The control of the quality of the production of such medications is strict and the assessment of the benefit\u2010risk ratio of these interventions is regulated by official recommendations which follow an evidence\u2010based approach. Ayurveda Indian medicine has used Mucuna Pruriens (MP) for the treatment of PD since ancient times. MP includes LD as an active moiety, among many others. A literature search was conducted between 1978\u20102012 with the keywords Parkinson\u2019s disease, ayurveda or mucuna pruriens. MP antagonized the effects of 6OHDA lesions in rats and when administered chronically it showed lower dyskinetic potential compared to L\u2010DOPA. MP also reduced Parkinsonian symptoms in an MPTP treated monkey with less dyskinesias compared to L\u2010DOPA. Four clinical trials of MP for PD treatment were found. Initially they were open\u2010label, uncontrolled studies, suggesting that MP might reduce parkinsonism severity. One double\u2010blind randomized crossover study was conducted in 8 PD patients, employing acute challenges of levodopa or MP. It showed that the effect of MP had a faster onset than LD, with shorter latencies to peak and increased on\u2010time. No other medium\u2010term (i.e., 6 months) randomized\u2010controlled trials (RCT) are available. According to the MDS EBM taskforce working procedures, an intervention is considered as \u201cefficacious\u201d when there is at least one high quality randomized controlled trial (RCT) showing a positive effect on studied outcomes with no conflicting data from other RCTs. Based on these premises, there is insufficient evidence to conclude the efficacy of MP in the treatment of PD. Thus its use in clinical practice remains open to investigation. It must also be emphasized that various MP formulations can be used, raising concerns about their quality, which is difficult to control, as regulation is limited. Impurities or variations in active moieties, can lead to unexpected adverse drug reactions. In conclusion, the use of MP in PD treatment remains open to investigation and thus cannot be recommended for clinical useInTech2013info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/16221848-884610.5772/56251P\u00e9rez Lloret, S., Rey M. V., Rascol, O. Ayurveda medicine for the treatment of Parkinson's disease [en l\u00ednea]. International Journal of Integrative Medicine. 2013, 1 (6). doi: 10.5772/56251. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1622International Journal of Integrative Medicine 2013, 1 (6)reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Cat\u00f3lica Argentinainstacron:UCAengenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2023-09-20T11:25:23Zoai:ucacris:123456789/1622Institucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852023-09-20 11:25:26.1Repositorio Institucional (UCA) - Pontificia Universidad Cat\u00f3lica Argentinafalse\n|\n|dc.title.none.fl_str_mv||\nAyurveda medicine for the treatment of Parkinson's disease\n|\n|title||\nAyurveda medicine for the treatment of Parkinson's disease\n|\n|spellingShingle||\nAyurveda medicine for the treatment of Parkinson's disease\n|\nP\u00e9rez Lloret, Santiago\nMEDICINA AYURVEDA\nENFERMEDAD DE PARKINSON\nTRATAMIENTO\nENFERMEDADES NEUROGENERATIVAS\n|title_short||\nAyurveda medicine for the treatment of Parkinson's disease\n|\n|title_full||\nAyurveda medicine for the treatment of Parkinson's disease\n|\n|title_fullStr||\nAyurveda medicine for the treatment of Parkinson's disease\n|\n|title_full_unstemmed||\nAyurveda medicine for the treatment of Parkinson's disease\n|\n|title_sort||\nAyurveda medicine for the treatment of Parkinson's disease\n|\n|dc.creator.none.fl_str_mv||\nP\u00e9rez Lloret, Santiago\n|\nRey, Ver\u00f3nica\nRascol, Olivier\n|author||\nP\u00e9rez Lloret, Santiago\n|\n|author_facet||\nP\u00e9rez Lloret, Santiago\n|\nRey, Ver\u00f3nica\nRascol, Olivier\n|author_role||\nauthor\n|\n|author2||\nRey, Ver\u00f3nica\n|\nRascol, Olivier\n|author2_role||\nauthor\n|\nauthor\n|dc.subject.none.fl_str_mv||\nMEDICINA AYURVEDA\n|\nENFERMEDAD DE PARKINSON\nTRATAMIENTO\nENFERMEDADES NEUROGENERATIVAS\n|topic||\nMEDICINA AYURVEDA\n|\nENFERMEDAD DE PARKINSON\nTRATAMIENTO\nENFERMEDADES NEUROGENERATIVAS\n|dc.description.none.fl_txt_mv||\nFil: P\u00e9rez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacolog\u00eda Cl\u00ednica y Neurociencias; Francia\n|\nFil: P\u00e9rez Lloret, Santiago. Pontificia Universidad Cat\u00f3lica Argentina. Facultad de Medicina. Laboratorio de Cl\u00ednica Farmacol\u00f3gica y Epidemiolog\u00eda; Argentina\nFil: Rey, Ver\u00f3nica. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacolog\u00eda Cl\u00ednica y Neurociencias; Francia\nFil: Rey, Ver\u00f3nica. Pontificia Universidad Cat\u00f3lica Argentina. Facultad de Medicina. Laboratorio de Cl\u00ednica Farmacol\u00f3gica y Epidemiolog\u00eda; Argentina\nFil: Rascol, Olivier. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacolog\u00eda Cl\u00ednica y Neurociencias; Francia\nAbstract: Abstract In most western countries, the symptomatic management of Parkinson\u2019s Disease (PD) is usually achieved with medicinal products including levodopa (LD), dopamine agonists, MAO\u2010B inhibitors, COMT inhibitors, antimuscarinics and amantadine. The control of the quality of the production of such medications is strict and the assessment of the benefit\u2010risk ratio of these interventions is regulated by official recommendations which follow an evidence\u2010based approach. Ayurveda Indian medicine has used Mucuna Pruriens (MP) for the treatment of PD since ancient times. MP includes LD as an active moiety, among many others. A literature search was conducted between 1978\u20102012 with the keywords Parkinson\u2019s disease, ayurveda or mucuna pruriens. MP antagonized the effects of 6OHDA lesions in rats and when administered chronically it showed lower dyskinetic potential compared to L\u2010DOPA. MP also reduced Parkinsonian symptoms in an MPTP treated monkey with less dyskinesias compared to L\u2010DOPA. Four clinical trials of MP for PD treatment were found. Initially they were open\u2010label, uncontrolled studies, suggesting that MP might reduce parkinsonism severity. One double\u2010blind randomized crossover study was conducted in 8 PD patients, employing acute challenges of levodopa or MP. It showed that the effect of MP had a faster onset than LD, with shorter latencies to peak and increased on\u2010time. No other medium\u2010term (i.e., 6 months) randomized\u2010controlled trials (RCT) are available. According to the MDS EBM taskforce working procedures, an intervention is considered as \u201cefficacious\u201d when there is at least one high quality randomized controlled trial (RCT) showing a positive effect on studied outcomes with no conflicting data from other RCTs. Based on these premises, there is insufficient evidence to conclude the efficacy of MP in the treatment of PD. Thus its use in clinical practice remains open to investigation. It must also be emphasized that various MP formulations can be used, raising concerns about their quality, which is difficult to control, as regulation is limited. Impurities or variations in active moieties, can lead to unexpected adverse drug reactions. In conclusion, the use of MP in PD treatment remains open to investigation and thus cannot be recommended for clinical use\n|description||\nFil: P\u00e9rez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacolog\u00eda Cl\u00ednica y Neurociencias; Francia\n|\n|publishDate||\n2013\n|\n|dc.date.none.fl_str_mv||\n2013\n|\n|dc.type.none.fl_str_mv||\ninfo:eu-repo/semantics/article\n|\ninfo:eu-repo/semantics/publishedVersion\nhttp://purl.org/coar/resource_type/c_6501\ninfo:ar-repo/semantics/articulo\n|format||\narticle\n|\n|status_str||\npublishedVersion\n|\n|dc.identifier.none.fl_str_mv||\nhttps://repositorio.uca.edu.ar/handle/123456789/1622\n|\n1848-8846\n10.5772/56251\nP\u00e9rez Lloret, S., Rey M. V., Rascol, O. Ayurveda medicine for the treatment of Parkinson's disease [en l\u00ednea]. International Journal of Integrative Medicine. 2013, 1 (6). doi: 10.5772/56251. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1622\n|url||\nhttps://repositorio.uca.edu.ar/handle/123456789/1622\n|\n|identifier_str_mv||\n1848-8846\n|\n10.5772/56251\nP\u00e9rez Lloret, S., Rey M. V., Rascol, O. Ayurveda medicine for the treatment of Parkinson's disease [en l\u00ednea]. International Journal of Integrative Medicine. 2013, 1 (6). doi: 10.5772/56251. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1622\n|dc.language.none.fl_str_mv||\neng\n|\neng\n|language||\neng\n|\n|dc.rights.none.fl_str_mv||\ninfo:eu-repo/semantics/openAccess\n|\nhttps://creativecommons.org/licenses/by-nc-sa/4.0/\n|eu_rights_str_mv||\nopenAccess\n|\n|rights_invalid_str_mv||\nhttps://creativecommons.org/licenses/by-nc-sa/4.0/\n|\n|dc.format.none.fl_str_mv||\napplication/pdf\n|\n|dc.publisher.none.fl_str_mv||\nInTech\n|\n|publisher.none.fl_str_mv||\nInTech\n|\n|dc.source.none.fl_str_mv||\nInternational Journal of Integrative Medicine 2013, 1 (6)\n|\nreponame:Repositorio Institucional (UCA)\ninstname:Pontificia Universidad Cat\u00f3lica Argentina\ninstacron:UCA\n|reponame_str||\nRepositorio Institucional (UCA)\n|\n|collection||\nRepositorio Institucional (UCA)\n|\n|instname_str||\nPontificia Universidad Cat\u00f3lica Argentina\n|\n|instacron_str||\nUCA\n|\n|institution||\nUCA\n|\n|repository.name.fl_str_mv||\nRepositorio Institucional (UCA) - Pontificia Universidad Cat\u00f3lica Argentina\n|\n|repository.mail.fl_str_mv||\nclaudia_fernandez@uca.edu.ar\n|\n|_version_||\n1777569963204149248\n|\n|score||\n12.888536\n|", "language": null, "image": null, "pagetype": null, "links": ["#content", "http://www.argentina.gob.ar/", "https://www.argentina.gob.ar", "https://www.argentina.gob.ar/ciencia", "/vufind/", "/vufind/Search/Advanced", "/vufind/", "/vufind/Record/RIUCA_b5c33442405717d8e78d138e09bd5997/Cite", "/vufind/Record/RIUCA_b5c33442405717d8e78d138e09bd5997/Export", "/vufind/Record/RIUCA_b5c33442405717d8e78d138e09bd5997/Export?style=RefWorks", "/vufind/Record/RIUCA_b5c33442405717d8e78d138e09bd5997/Export?style=EndNoteWeb", "/vufind/Record/RIUCA_b5c33442405717d8e78d138e09bd5997/Export?style=EndNote", "#", "/vufind/Author/Home?author=P%C3%A9rez+Lloret%2C+Santiago", "/vufind/Author/Home?author=Rey%2C+Ver%C3%B3nica", "/vufind/Author/Home?author=Rascol%2C+Olivier", "https://repositorio.uca.edu.ar/handle/123456789/1622", "#collapseDetail", "/vufind/Record/RIUCA_f796c59c2d66e59dbe7b62c49616927c", "/vufind/Record/RIUCA_8edeb5cf4a360a9c7593f002136a983f", "/vufind/Record/RIUCA_b47c41bdf3f55c1241da4b61db3d598a", "/vufind/Record/RIUCA_0b0f8db1342c5371ac85a1a43fdb4d42", "/vufind/Record/RIUCA_3cf134a4836fc601982425e6c703f9be", "https://www.argentina.gob.ar/turnos", "https://www.argentina.gob.ar/jefatura/innovacion-publica/administrativa/tramites-a-distancia", "https://www.argentina.gob.ar/miargentina/mesadeayuda", "https://www.argentina.gob.ar/pais", "https://www.argentina.gob.ar/normativa", "https://www.argentina.gob.ar/organismos", "https://www.argentina.gob.ar/jefatura/mapa-del-estado", "https://www.argentina.gob.ar/acerca", "https://www.argentina.gob.ar/terminos-y-condiciones", "https://www.argentina.gob.ar/sugerencias"]}